Research Analysts Offer Predictions for Annexon Q3 Earnings

Annexon, Inc. (NASDAQ:ANNX) – Equities research analysts at HC Wainwright reduced their Q3 2026 earnings per share (EPS) estimates for shares of Annexon in a research report issued on Thursday, August 13th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($0.27) per share for the quarter, down from their previous forecast of ($0.22). HC Wainwright currently has a “Buy” rating and a $14.00 target price on the stock. The consensus estimate for Annexon’s current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for Annexon’s FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.39) EPS, FY2029 earnings at $0.03 EPS and FY2030 earnings at $0.45 EPS.

Annexon (NASDAQ:ANNX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04).

Other equities research analysts have also issued research reports about the company. Wall Street Zen lowered Annexon from a “sell” rating to a “strong sell” rating in a research report on Saturday. Needham & Company LLC lifted their target price on shares of Annexon from $11.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Citizens Jmp upgraded shares of Annexon from an “underperform” rating to a “market perform” rating in a research note on Thursday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Annexon in a report on Friday, July 17th. Finally, Citigroup started coverage on shares of Annexon in a research report on Tuesday, July 21st. They set a “market underperform” rating on the stock. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $15.33.

Annexon Trading Down 3.0%

Shares of ANNX stock opened at $5.13 on Monday. Annexon has a twelve month low of $2.03 and a twelve month high of $7.18. The stock has a market cap of $972.55 million, a P/E ratio of -4.42 and a beta of 1.18. The stock has a 50 day moving average of $5.35 and a 200 day moving average of $5.49.

Institutional Trading of Annexon

Institutional investors and hedge funds have recently made changes to their positions in the business. CIBC Bancorp USA Inc. acquired a new position in shares of Annexon during the 3rd quarter worth approximately $31,000. Engineers Gate Manager LP acquired a new stake in Annexon in the 2nd quarter valued at $32,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock worth $35,000 after acquiring an additional 2,785 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Annexon in the 4th quarter worth $50,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Annexon during the fourth quarter worth $52,000.

Insiders Place Their Bets

In other Annexon news, Director Muneer A. Satter purchased 613,497 shares of Annexon stock in a transaction that occurred on Thursday, May 28th. The stock was bought at an average price of $5.41 per share, with a total value of $3,319,018.77. Following the acquisition, the director owned 10,342,134 shares of the company’s stock, valued at $55,950,944.94. This trade represents a 6.31% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 10.31% of the company’s stock.

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.